HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.

AbstractOBJECTIVE:
To evaluate whether exposure to 17α-hydroxyprogesterone caproate is associated with the rate of peripartum infection in women who deliver preterm and their neonates.
METHODS:
This is a retrospective cohort study of patients who delivered before 37 weeks of gestation at a tertiary care hospital between July 1, 2005, and December 31, 2012. Women in the case group (women exposed to 17α-hydroxyprogesterone caproate) were matched to women in a control group (unexposed patients) by gestational age and delivery date. The primary outcome was a composite infection rate comprising histologic or clinical chorioamnionitis, endometritis, or early-onset neonatal sepsis. To detect a 15% difference in composite infection rate between women exposed to 17α-hydroxyprogesterone caproate and those unexposed (two-tailed α=0.05 and power=80%), 183 patients per group were required. Logistic regression was performed to control for a history of prior spontaneous preterm birth and exposure to betamethasone.
RESULTS:
The primary outcome frequency for women exposed to 17α-hydroxyprogesterone caproate was 34.6% (64 patients) compared with 33% (61 patients) in those unexposed (P=.74). There was no significant difference between women exposed to 17α-hydroxyprogesterone caproate and those unexposed in frequency of clinical chorioamnionitis (1.9% compared with 1.1%, P=.66), histologic chorioamnionitis (39.4% compared with 40%, P=.92), or early-onset neonatal sepsis (2.7% compared with 1.1%, P=.28). A total of 7.1% of women exposed to 17α-hydroxyprogesterone caproate developed endometritis compared with 2.7% of those unexposed (P=.05). The adjusted odds ratio for the primary outcome in women exposed to 17α-hydroxyprogesterone caproate was 0.65 (95% confidence interval 0.31-1.38).
CONCLUSION:
Exposure to 17α-hydroxyprogesterone caproate does not increase the risk of peripartum infection among women who deliver preterm or their neonates.
LEVEL OF EVIDENCE:
II.
AuthorsAlexandra D Mainiero, Dwight J Rouse, Vrishali Lopes, Brenna L Hughes
JournalObstetrics and gynecology (Obstet Gynecol) Vol. 126 Issue 1 Pg. 103-8 (Jul 2015) ISSN: 1873-233X [Electronic] United States
PMID26241262 (Publication Type: Evaluation Study, Journal Article)
Chemical References
  • Hydroxyprogesterones
  • Progestins
  • 17 alpha-Hydroxyprogesterone Caproate
Topics
  • 17 alpha-Hydroxyprogesterone Caproate
  • Adult
  • Chorioamnionitis (chemically induced, epidemiology)
  • Cohort Studies
  • Endometritis (chemically induced, epidemiology)
  • Female
  • Humans
  • Hydroxyprogesterones (adverse effects, therapeutic use)
  • Infant, Newborn
  • Logistic Models
  • Pregnancy
  • Premature Birth (prevention & control)
  • Progestins (adverse effects, therapeutic use)
  • Retrospective Studies
  • Risk Factors
  • Sepsis (chemically induced, epidemiology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: